What is CPIX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CPIX?

P/E (TTM) is n/a and 52-week range is $1.85 to $9.28 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CPIX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CPIX?

The company profile lists revenue (TTM) near $31M, net income (TTM) near -$1.08B, EPS (TTM) near -$0.72 when available from the market-data feed. Figures are informational and may lag live markets.

Does CPIX show a dividend on Chartloom?

The overview lists ex-dividend date Aug 3, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Cumberland Pharmaceuticals Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Nashville, Tennessee, US, 15M shares outstanding, ISIN US2307701092 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cumberland Pharmaceuticals Inc.

$CPIX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 93 full-time employees. The company went IPO on 2009-08-11. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. The company is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.

Employees

Website

www.cumberlandpharma.com/

IPO

2009-08-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US2307701092

Headquarters

Nashville, Tennessee, US

Shares outstanding

15M

NAICS sector

Manufacturing

Institutional ownership

15.89%

Browse other companiesFree AI scores and summaries for more stocks